Tarsus Pharamceuticals

Medical Science Liaison (MSL) - South Central

Houston, Texas, United States

Not SpecifiedCompensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Medical Affairs, HealthcareIndustries

Requirements

Candidates must hold a Doctor of Optometry (OD), Medical Degree (MD), Doctor of Pharmacy (PharmD), or PhD degree with demonstrated expertise in eye care. Preferred experience includes at least three years as a Medical Science Liaison in eye care, or three years of clinical experience in eyecare with at least one year of industry experience, or seven plus years of clinical practice in eyecare.

Responsibilities

The Medical Science Liaison will manage key opinion leader (KOL) optometrists and ophthalmologists in a designated region, ensuring compliant conduct, serve as the primary medical affairs KOL point of contact for scientific exchange, collect actionable insights to shape medical strategy, provide whole practice education to optometric and ophthalmic centers, provide resources for disease state education, instruct customers on investigator initiated trial and medical information procedures, identify and recommend KOLs for various projects, plan KOL engagements and attend scientific sessions, liaise with medical societies, present scientific evidence to the payer community, participate in continual optimization of training and processes, host local scientific exchanges, participate in compliant engagements with cross-functional teams, provide clinical trial support, and manage territory budget and CRM entries.

Skills

KOL Management
Medical Affairs
Scientific Exchange
Clinical Education
Payer Communication
Clinical Trial Support
CRM Management
Territory Management

Tarsus Pharamceuticals

Develops treatments for eye care diseases

About Tarsus Pharamceuticals

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company is also working on other potential treatments for conditions such as Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong pipeline of future products. Their goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.

Key Metrics

Irvine, CaliforniaHeadquarters
2017Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in ophthalmic treatments challenges Tarsus's market position.
Potential clinical trial delays could affect Tarsus's product pipeline.
Supply chain constraints may hinder XDEMVY's production and distribution.

Differentiation

Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.

Upsides

Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
Telemedicine rise offers new marketing opportunities for Tarsus's products.
FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.

Land your dream remote job 3x faster with AI